Sanofi’s Riliprubart earns USFDA orphan drug designation for organ transplant complication
In a promising development for transplant medicine, global healthcare leader Sanofi has announced that its investigational therapy riliprubart has received Orphan Drug Designation from the U.S. Food and Drug Administration.